...
首页> 外文期刊>European Heart Journal: The Journal of the European Society of Cardiology >Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection.
【24h】

Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection.

机译:经皮冠状动脉介入治疗期间的围手术期心肌损伤:心脏保护的重要目标。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Percutaneous coronary intervention (PCI) has become the predominant procedure for coronary revascularization in patients with both stable and unstable coronary artery disease (CAD). Over the past two decades, technical advances in PCI have resulted in a better and safer therapeutic procedure with minimal procedural complications. However, about 30% of patients undergoing elective PCI sustain myocardial injury arising from the procedure itself, the extent of which is significant enough to carry prognostic importance. The peri-procedural injury which accompanies PCI might therefore reduce some of the beneficial effects of coronary revascularization. The availability of more sensitive serum biomarkers of myocardial injury such as creatine phosphokinase MB isoenzyme (CK-MB), Troponin T, and Troponin I has enabled the quantification of previously undetectable myocardial injury. Peri-procedural myocardial injury (PMI) can also be visualized by cardiac magnetic resonance imaging, a technique which allows the detection and quantification of myocardial necrosis following PCI. The identification of CAD patients at greatest risk of sustaining PMI during PCI would allow targeted treatment with novel therapies capable of limiting the extent of PMI or reducing the number of patients experiencing PMI.
机译:经皮冠状动脉介入治疗(PCI)已成为患有稳定和不稳定冠状动脉疾病(CAD)的患者进行冠脉血运重建的主要方法。在过去的二十年中,PCI的技术进步带来了更好,更安全的治疗程序,同时将手术并发症降至最低。但是,约有30%的行选择性PCI的患者会因手术本身而遭受心肌损伤,其程度足以引起预后的重视。因此,PCI引起的围手术期损伤可能会降低冠状动脉血运重建的某些有益作用。诸如心肌肌酸磷酸激酶MB同工酶(CK-MB),肌钙蛋白T和肌钙蛋白I等更敏感的心肌损伤血清生物标志物的可用性使量化先前无法检测到的心肌损伤成为可能。围手术期心肌损伤(PMI)也可以通过心脏磁共振成像来可视化,该技术可以检测和量化PCI后的心肌坏死。对在PCI期间维持PMI风险最大的CAD患者的识别将允许使用能够限制PMI程度或减少经历PMI的患者人数的新疗法进行靶向治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号